International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 5, Issue 2, pp: (584-589), Month: October 2017 - March 2018, Available at: www.researchpublish.com

Updated Review of Diagnosis and Management of Cerebral Venous Thrombosis

[1]Nasser Abdullah N Aldawsari, [2]Bassam Awad M Alzubaidi, [3]Sultan Thayer N Alharbi

Abstract: **This review aims to summarize the existing evidence regarding the diagnostic methods and the management of CVT, including heparin and thromblolysis. Electronic Databases (MEDLINE, PubMed, and Emabse) were used to conduct a comprehensive review on management of Cerebral Venous Thrombosis in general and specifically the diagnostic approaches and treatment options. CVT is an uncommon reason for acute stroke, yet a high index of suspicion ought to be preserved in any type of patient with unexplained encephalopathy or headaches, headaches refractory to treatment or high ICP. Anticoagulation should be started even in patients of ICH. It requires precise medical diagnosis because the pathophysiology and treatment vary from arterial stroke. Headache is the initial symptom in more than 70% and the predominant symptom in approximately 90% of patients with cerebral venous thrombosis (CVT).**

Keywords: **cerebral venous thrombosis (CVT), headaches refractory to treatment or high ICP.**

1. INTRODUCTION

Cerebral venous thrombosis (CVT) is a fairly unusual reason of stroke, accounting for just 0.5 to 1% of all acute strokes [1].It commonly offers with brand-new beginning of relentless headache or as a disorder of increased intracranial pressure (ICP). Approximately, one-third of patients might develop seizures, whereas others may develop a focal neurologic shortage or encephalopathy. A selection of underlying risk factors could promote CVT, including prothrombotic states (both gotten and inherited), medicines, such as oral contraceptive pills, pregnancy and the puerperium, hatred, infection, mechanical elements, and miscellaneous problems. In the biggest multinational multicenter potential mate study on CVT to date, the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT), both most typical danger factors were a hidden thrombophilia (34%) or the direct exposure to contraceptive pills (54%) [2].At the very least one danger variable was recognized in 85% of cases, and two or even more in 44% of patients [2].

This review aims to summarize the existing evidence regarding the diagnostic methods and the management of CVT, including heparin and thromblolysis.

2. METHODOLOGY

Electronic Databases (MEDLINE, PubMed, and Emabse) were used to conduct a comprehensive review on management of Cerebral Venous Thrombosis in general and specifically the diagnostic approaches and treatment options. Restriction to English language published study up to December, 2017 was applied. Furthermore, references list of identified studies was searched for more relevant articles.

3. DISCUSSION

- **Diagnosis:**

Although extremely sensitive for detecting even little associated hemorrhages (Figure 1), plain computed tomography (CT) imaging is not suitable to rule out CVT. Contrast-enhanced imaging could reveal indirect indications of a thrombus in a huge sinus ('em pty triangular indication'). A bleeding cortical vein (' cord indicator') and the thick triangular indication suggesting a fresh thrombus in the posterior part of the remarkable saggital sinus or the sigmoid sinus may be seen on unenhanced CT. Imaging of the venous system is the crucial to diagnosis. Reliable recognition of CVT could be

accomplished with the enhancement of vibrant venous CT-angiography making use of pieces of 1-1.5 mm size. With the application of multiplanar repair, level of sensitivity reaches 95% and specificity 91% compared to digital subtraction angiography [3].Like CT imaging, plain MRI is not appropriate to most definitely dismiss CVT. Rather, the method of selection is integrated MRI and contrast-enhanced magnetic resonance (MR) venous angiography [4].Although interpretation of MR angiography is a lot more intricate, it allows more advanced verdicts and is premium in the detection of cortical venous apoplexy contrasted with CT angiography. Due to the fact that the MRI signal modifications with time, different MRI series and slice alignments should be integrated. Thrombosis of the sinus does not cause signal loss in the axial and sagittal T1- and T2-sequences yet ideally may show up hyperintense as a result of its content of methemoglobin. Depending on the structure and localization of the thrombus, T1- or T2-weighted series and vulnerability heavy imaging are highly delicate for straight detection of the thrombus [5], [6].Hence, besides the thrombosed sinus, also solitary thrombosed veins could be detected as hypointense frameworks [7].However, these must be separated from local subarachnoid or subpial hemorrhages, which might likewise look like hypointense on T2- heavy imaging. Subarachnoid hemorrhage localized along a sulcus might additionally be a measure of a single cortical capillary thrombosis [8].Adhering to comparison enhancement, comparison is spared in the thrombosed sinus on MRI, like on CT. In a thrombus with a high methemoglobin degree, there could be a hyperintense signal in the time-of-flight angiography that ought to not be confused with a flow signal. Presence of normal frameworks in the intracranial dural sinuses (arachnoid granulations, intrasinus fibrotic bands) should not be misinterpreted as CVT, which might result in unnecessary anticoagulation [9], [10]. Also, a hypoplastic left lateral sinus prevails and should be separated from CVT. With CT and MRI methods continuously advancing, traditional digital subtraction angiography is rarely indicated anymore for the discovery of CVT and need to just be taken into consideration for interventional purposes or in instance CT or MR venography is not available.

Acute CVT presenting with neurological shortages is highly associated (97%) with d-dimer levels of > 500 ng/ml [11].On the other hand, d-dimer degrees of > 500 ng/ml [11].On the other hand, d-dimer degrees< 500 ng/ml do not rule out CVT, specifically when presenting with separated headache only. As a result, although typical d-dimer degrees make the visibility of CVT not likely, exemption of CVT need to not be based on d-dimer dimension just.

TABLE 1.Clinical Manifestations of Cerebral Venous Thrombosis

Clinical Presentation	Frequency
Headaches	90%
Seizures	40%
Focal deficit (eg, hemiparesis, aphasia)	20%
Decreased level of consciousness	14%
Isolated headaches	15%
Visual loss	13%

TABLE 2. Differential Diagnosis of Cerebral Venous Thrombosis

Idiopathic intracranial hypertension (pseudotumor cerebri)
Arterial ischemic stroke b Primary intracerebral hemorrhage
Hemorrhagic stroke due to a vascular malformation b Meningitis/encephalitis
Brain abscess
Systemic lupus erythematosus (by far the most common differential diagnosis, affecting mostly women as in cerebral venous thrombosis [CVT])
Sarcoidosis (may have a presentation similar to CVT)
Antiphospholipid syndrome (may have a presentation similar to CVT)
Gliomatosis cerebri

- **Treatment:**

Like in ischemic stroke, therapy of acute CVT calls for cardiopulmonary tracking and stroke system treatment to detect scientific damage and handle issues in time. In line with the therapeutical standards for peripheral deep venous thrombosis (DVT), anticoagulation is additionally the therapy of selection for CVT. First anticoagulation with heparin is believed to stop the development of thrombosis, to minimize the threat of pulmonary blood clot and to stop re-occlusion of those

vessels that have already been recanalized by internally generated fibrinolytics. Verified CVT should for that reason be treated with heparin even in the existence of a linked intracranial hemorrhage. Septic or transmittable CVT are treated with prescription antibiotics according to the underlying contagious agent and emphasis. In particular instances, surgical treatment can be needed to regulate the focus of infection. In spite of anti-infective therapy, death is higher compared to noninfectious CVT and treatment with anticoagulation is warranted even in the lack of evidence from controlled tests.

Heparin:

The current guidelines for the diagnosis and therapy of CVT just recently published by the American Heart and Stroke Association along with the European Federation of Neurological Societies provide suggestions on anticoagulation for CVT [12], [13]. Evidence for efficacy of treatment with heparin in acute CVT comes from two randomized placebo-controlled research studies that with each other consisted of 79 patients. Einhäupl et al. compared doseadapted partial thromboplastin time-controlled intravenous therapy with unfractionated heparin (UFH) versus placebo in 20 patients with CVT: in the heparin group, eight patients revealed total restitution, and all patients made it through with no additional bleeding complications observed, whereas in the placebo group, just one patient revealed complete recovery, 3 patients passed away and 2 patients developed brand-new intracerebral hemorrhages [14] de Bruijn et al. explored effectiveness and safety and security of treatment with nadroparin 2 × 90 mg/kg/days for 3 weeks in subcutaneous application versus placebo in 59 CVT patients [15].There was a nonsignificant trend in favor of therapy with low-molecularweight heparin (LMWH), and neither brand-new ICH neither a rise in ICH size was observed. A meta-analysis of both researches showed a 54% family member risk reduction in death and severe special needs with heparin therapy [16].Although this meta-analysis was not considerable either, results of both researches show treatment with heparin for CVT to be risk-free and to minimize the danger of unfavorable progression.

It is not known whether intravenous dose-adapted therapy with UFH and weight-adapted treatment with LMWH are equivalent. A current nonrandomized potential observational research in patients with CVT found therapy with LMWH to be extra reliable and associated with fewer bleeding complications [17].Especially, patients with hemorrhagic infarctions seemed to gain from treatment with LMWH. For factors of practicability, regular application of LMWH treatment for CVT may be better due to the fact that intravenous accessibility or normal blood checks are not called for. The European guidelines for therapy of CVT recommend using weight-adapted LMWH [13].Because coagulation stabilizes within 1-2 h after discontinuation of intravenous heparinization, UFH may be useful for the therapy of critically unwell patients (ICU patients) or in situation surgical interventions are imminent.

Thrombolysis:

There are no randomized controlled research studies to verify effectiveness and safety of locally used thrombolysis in CVT [18].Noncontrolled case records have shown high rates of recanalization over long time intervals-frequently days-adhering to locally applied urokinase or rt-PA alone or in mix with thrombectomy, however hemorrhaging difficulties were a lot more frequent [13].Particularly, patients with large space-occupying hemorrhagic infarcts do not gain from thrombolytic treatment because a rise in hemorrhage dimension increases the unavoidable herniation [19].Nonetheless, in patients with thrombosis of the inner cranial veins or substantial CVT without connected hemorrhage, locally used thrombolysis may be a choice and should be considered as a specific therapy effort after failure of traditional heparin treatment. Possibly the major indication for neighborhood thrombolysis is several sinus occlusions including the jugular veins with no egress of blood because these patients have very poor outcomes and markedly raised intracranial pressure (ICP). An organized evaluation that included 169 patients treated with local thrombolysis showed a feasible benefit in patients with severe CVT [20].Technically, thrombolysis is slowly carried out utilizing an intra-arterially positioned microcatheter and might be integrated with transvenous thrombectomy if necessary [19], [21].Nevertheless, the optimum techniques for thrombolytic treatment (dosage, methods of application, gain access to and use heparin) have not been determined yet. Similarly, mechanical thrombectomy is only sustained by instance reports however could be taken into consideration if professional deterioration occurs regardless of using anticoagulation [12].By comparison, intravenous thrombolysis is not advised for the treatment of CVT.

Elevated ICP:

Although elevated ICP could be discovered in up to 50% of patients with CVT, most patients do not require details ICP-lowering therapy. Boosted ICP can be taken care of best with sufficient anticoagulation by enhancing the venous drainage that causes a reduction of ICP. In patients with symptomatic intracranial hypertension and unavoidable loss of vision,

duplicated back leaks might be had to drain pipes CSF prior to anticoagulation can be begun. If medical signs and symptoms proceed in spite of repeated CSF drainage, long-term CSF drainage could be required. Particular ICP-lowering treatment is indicated in less compared to 20% of all patients. General policies of ICP-lowering therapy need to be used (upper body elevation, hyperventilation, intravenous management of osmotherapeutic agents). However, these treatments have restricted period of action and are of little impact. One case record showed favorable result in six of eight patients after hemicraniectomy in spite of professional and radiological findings of herniation [22].Specifically, patients providing with big hemorrhagic infarctions and imminent side herniation ought to be supplied timely surgical decompression without removal of the hematoma or infarcted location [13].Anticoagulation should be proceeded within 12-24 h after surgical treatment. Volume constraints need to be avoided. Since of its prothrombotic task and no tried and tested advantage, therapy with steroids is not advised.

Antiepileptic medication:

Roughly 40-50 % of patients with CVT develop epileptic seizures leading to acute or lingering clinical deterioration [23], [24].Particularly, patients offering with a combination of cortical apoplexy, electric motor shortages and hemorrhagic infarctions are vulnerable to create seizures or even epileptic status. In this case, instant antiepileptic treatment is shown ideally using intravenous application. Patients providing with very early seizures and hemorrhagic infarctions are at highest threat of creating symptomatic epilepsy and could take advantage of lasting antiepileptic treatment (12 months). In all various other patients, antiepileptic therapy should be terminated after a seizure-free period of 3-6 months. In contrast to the high incidence of seizure activity during the acute stage, the risk to create recurring epilepsy following CVT is relatively small. In the absence of evidence to support precautionary antiepileptic treatment in CVT, prophylactic treatment could be taken into consideration independently [24].

- **Secondary prevention in patients at risk:**

Suggestions for CVT avoidance in grownups are in conformity with the present standards for the prevention of DVT in patients at high threat of venous thromboembolism (VTE)- that is, treatment with anticoagulation in risk scenarios. Prophylaxis with weight-adapted LMWH need to additionally be offered in threat scenarios (e.g., immobilization > 4 days, steroid therapy, flight > 4 h), along with in infants and teenagers with a history of CVT [25].

There is little knowledge concerning recurrent CVT during a new pregnancy. One retrospective study located no reappearance of CVT throughout 22 subsequent maternities [26].Arise from several case reports also indicate that the risk of recurrence is not raised [27].Likewise, the risk for a repeat DVT throughout a brand-new pregnancy is reduced after a pregnancy-associated peripheral DVT, specifically if no acquired or gotten thrombophilia exists. Women with either prior extracerebral or CVT who are pregnant or plan to conceive should be tested for thrombophilia that may help to lower the specific risk of recurrence throughout subsequent pregnancies. Counselling concerning symptoms suggestive of CVT and neurological security during a succeeding pregnancy is suggested. Anticoagulation with weight-adapted LMWH for 6 weeks after delivery is recommended in patients with a background of CVT that is in line with recommendations from the standards for prevention of DVT, as the postpartum period brings the greatest everyday danger of establishing DVT and CVT.

4. CONCLUSION

CVT is an uncommon reason for acute stroke, yet a high index of suspicion ought to be preserved in any type of patient with unexplained encephalopathy or headaches, headaches refractory to treatment or high ICP. Anticoagulation should be started even in patients of ICH. It requires precise medical diagnosis because the pathophysiology and treatment vary from arterial stroke. Headache is the initial symptom in more than 70% and the predominant symptom in approximately 90% of patients with cerebral venous thrombosis (CVT). Confirmed CVT needs to be treated with intravenous or low-molecular-weight heparin even in the presence of intracranial hemorrhage. Long-lasting anticoagulation is recommended only in patients struggling with an extreme coagulopathy or recurrent CVT. Understanding the short-term and chronic risk aspects is the crucial to prognosis for recurrent CVT and whether lasting treatment with anticoagulation is required. In addition, although the outcomes after CVT are usually beneficial, they likewise rely on patient aspects, such as sex and the female-specific risk factors.

REFERENCES

[1] Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:2160.

[2] Ferro JM, Canha˜o P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35:664.

[3] Wetzel SG, Kirsch E, Stock KW, Kolbe M, Kaim A, Radue EW. Cerebral veins: comparative study of CT venography with intraarterial digital subtraction angiography. AJNR Am. J. Neuroradiol. 20(2), 249–255 (1999).

[4] Agid R, Shelef I, Scott JN, Farb RI. Imaging of the intracranial venous system. Neurologist 14(1), 12–22 (2008).

[5] Selim M, Fink J, Linfante I, Kumar S, Schlaug G, Caplan LR. Diagnosis of cerebral venous thrombosis with echoplanar T2*-weighted magnetic resonance imaging. Arch. Neurol. 59(6), 1021–1026 (2002).

[6] Leach JL, Fortuna RB, Jones BV, Gaskill-Shipley MF. Imaging of cerebral venous thrombosis: current techniques, spectrum of findings, and diagnostic pitfalls. Radiographics 26(Suppl. 1), S19–S41; discussion S42–S13 (2006).

[7] Linn J, Brückmann H. Cerebral venous and dural sinus thrombosis: state-of-the-art imaging. Klin. Neuroradiol. (2010).

[8] Urban PP, Müller-Forell W. Clinical and neuroradiological spectrum of isolated cortical vein thrombosis. J. Neurol. 252(12), 1476–1481 (2005).

[9] Alper F, Kantarci M, Dane S, Gumustekin K, Onbas O, Durur I. Importance of anatomical asymmetries of transverse sinuses: an MR venographic study. Cerebrovasc. Dis. 18(3), 236–239 (2004).

[10] Liang L, Korogi Y, Sugahara T et al. Normal structures in the intracranial dural sinuses: delineation with 3D contrastenhanced magnetization prepared rapid acquisition gradient-echo imaging sequence. Am. J. Neuroradiol. 23(10), 1739–1746 (2002).

[11] Kosinski CM, Mull M, Schwarz M et al. Do normal d-dimer levels reliably exclude cerebral sinus thrombosis? Stroke 35(12), 2820–2825 (2004).

[12] Saposnik G, Barinagarrementeria F, Brown RD Jr et al.; American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42(4), 1158–1192 (2011).

[13] Einhäupl K, Stam J, Bousser MG et al.; European Federation of Neurological Societies. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur. J. Neurol. 17(10), 1229–1235 (2010).

[14] Einhäupl KM, Villringer A, Meister W et al. Heparin treatment in sinus venous thrombosis. Lancet 338(8767), 597–600 (1991).

[15] de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 30(3), 484–488 (1999).

[16] Stam J, de Bruijn S, deVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst. Rev. CD002005 (2008).

[17] Coutinho JM, Ferro JM, Canhão P, Barinagarrementeria F, Bousser MG, Stam J; ISCVT Investigators. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke 41(11), 2575–2580 (2010).

[18] Ciccone A, Canhão P, Falcão F, Ferro JM, Sterzi R. Thrombolysis for cerebral vein and dural sinus thrombosis. Cochrane Database Syst. Rev. 1, CD003693 (2004).

[19] Stam J, Majoie CB, van Delden OM, van Lienden KP, Reekers JA. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study. Stroke 39(5), 1487–1490 (2008).

[20] Canhão P, Falcão F, Ferro JM. Thrombolytics for cerebral sinus thrombosis: a systematic review. Cerebrovasc. Dis. 15(3), 159–166 (2003).

[21] Rahman M, Velat GJ, Hoh BL, Mocco J. Direct thrombolysis for cerebral venous sinus thrombosis. Neurosurg. Focus 27(5), E7 (2009).

[22] Théaudin M, Crassard I, Bresson D et al. Should decompressive surgery be performed in malignant cerebral venous thrombosis?: a series of 12 patients. Stroke 41(4), 727–731 (2010).

[23] Masuhr F, Busch M, Amberger N et al. Risk and predictors of early epileptic seizures in acute cerebral venous and sinus thrombosis. Eur. J. Neurol. 13(8), 852–856 (2006).

[24] Ferro JM, Canhão P, Bousser MG, Stam J, Barinagarrementeria F; ISCVT Investigators. Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke 39(4), 1152–1158 (2008).

[25] Monagle P, Chalmers E, Chan A et al.; American College of Chest Physicians. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), 887S–968S (2008).

[26] Mehraein S, Ortwein H, Busch M, Weih M, Einhäupl K, Masuhr F. Risk of recurrence of cerebral venous and sinus thrombosis during subsequent pregnancy and puerperium. J. Neurol. Neurosurg. Psychiatr. 74(6), 814–816 (2003).

[27] Furie KL, Kasner SE, Adams RJ et al.; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42(1), 227–276 (2011).